StockData
Biodesix Inc logo

Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$9.88+0.09 (+0.92%)

Close on Nov 13, 2026Market cap $104.25MP/E –Yield –

Earnings

Biodesix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$24.00M
+10.1% on a year earlier
EPS, Q3 FY2026
-$0.75
-$1.16 a year earlier
Latest guidance
Lowered
Nov 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Biodesix's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$24.00M+10.1%-$0.75Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$26.90M+34.5%–Release
Q1 FY2026ended Mar 31, 2026May 4, 2026after the close$25.60M+42.2%-$0.81Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026after the close$28.80M+41.2%-$0.49Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025after the close$21.80M+19.8%-$1.16Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$20.00M+11.7%–Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close$18.00M+21.6%–Release
Q4 FY2024ended Dec 31, 2024Mar 3, 2025after the close$20.40M+38.8%-$0.06Release
Q3 FY2024ended Sep 30, 2024Nov 1, 2024before the open$18.20M+34.8%–Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$17.90M+50.4%-$0.08Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$14.80M+62.6%-$0.14Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Biodesix's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$101.00M – $103.00M$106.00M – $112.00MLoweredNov 5, 2026
total revenueFY2026$108.00M – $114.00M$108.00M – $114.00MReaffirmedAug 5, 2026
Gross MarginFY202680%–NewMay 4, 2026
gross marginsFY202680%80%ReaffirmedNov 5, 2026

Guidance vs results

The last range Biodesix gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$84.00M – $86.00M$88.60MΣ4QAbove range

Guidance history

Every forecast Biodesix put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026gross marginsFY202680%Reaffirmed
Nov 5, 2026total revenueFY2026$101.00M – $103.00MLowered
Aug 5, 2026total revenueFY2026$108.00M – $114.00MReaffirmed
May 4, 2026Gross MarginFY202680%New
May 4, 2026total revenueFY2026$108.00M – $114.00MNew
Feb 26, 2026Gross MarginFY202680%New
Feb 26, 2026total revenueFY2026$106.00M – $112.00MNew
Nov 3, 2025total revenueFY2025$84.00M – $86.00MNew
Aug 7, 2025total revenueFY2025$80.00M – $85.00MReaffirmed
May 13, 2025total revenueFY2025$80.00M – $85.00MLowered
Mar 3, 2025total revenueFY2025$92.00M – $95.00MNew
Nov 1, 2024revenueFY2024$70.00M – $72.00MReaffirmed
Aug 7, 2024total revenueFY2024$70.00M – $72.00MRaised
May 8, 2024total revenueFY2024$65.00M – $68.00MReaffirmed
Mar 1, 2024total revenueFY2024$65.00M – $68.00MNew
Nov 7, 2023total revenueFY2023$50.00M – $52.00MLowered
Aug 7, 2023total revenueFY2023$52.00M – $55.00MReaffirmed
May 11, 2023total revenueFY2023$52.00M – $55.00MReaffirmed
Mar 6, 2023total revenueFY2023$52.00M – $55.00MNew
Nov 3, 2022total revenueFY2022$37.50M – $39.50MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Biodesix filed with the SEC as exhibits to Form 8-K or 6-K

  1. Biodesix Announces Third Quarter 2026 Results and Highlights
    Results
  2. Biodesix Announces Second Quarter 2026 Results and Highlights
    Results
  3. Biodesix Announces First Quarter 2026 Results and Highlights
    Results
  4. Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
    Results
  5. Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
    Results
  6. Biodesix Announces Third Quarter 2025 Results and Highlights
    Results
  7. September 11, 2025 — Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a
    News
  8. Biodesix Announces Second Quarter 2025 Results and Highlights
    Results
  9. Biodesix Announces First Quarter 2025 Results and Highlights
    Results
  10. Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
    Results
  11. Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
    Results
  12. Biodesix Announces Third Quarter 2024 Results and Highlights
    Results
  13. diagnostic company addressing a large unmet need with limited competition © 2024 Biodesix, Inc. All rights reserved. 1 3Q24
    Update
  14. Biodesix Announces Second Quarter 2024 Results and Highlights
    Results
  15. Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
    Results

See a number that looks wrong?